Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC chemotherapy
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
TAC chemotherapy is a combination regimen consisting of three cytotoxic drugs: docetaxel (a taxane), doxorubicin (an anthracycline), and cyclophosphamide (an alkylating agent). It is primarily used as adjuvant or neoadjuvant therapy for breast cancer, especially in cases with a higher risk of recurrence. Each drug in the combination attacks cancer cells through different mechanisms: - Docetaxel disrupts microtubule function, inhibiting cell division. - Doxorubicin intercalates into DNA and inhibits topoisomerase II, causing DNA damage and apoptosis. - Cyclophosphamide crosslinks DNA strands, preventing cell replication. The combination exploits these complementary mechanisms to maximize tumor cell kill. The regimen is typically administered intravenously every 3 weeks for six cycles[1][2][3][4][7].
- Brand names
- Adriamycin (doxorubicin)Cytoxan (cyclophosphamide)Taxol (paclitaxel)Taxotere (docetaxel)
- Other names
- Taxotere Adriamycin Cyclophosphamidedocetaxel doxorubicin cyclophosphamideTAC regimen
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on TAC chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC chemotherapy.